{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:26:30Z","timestamp":1780449990306,"version":"3.54.1"},"reference-count":42,"publisher":"Index Copernicus","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pol Przegl Chir"],"published-print":{"date-parts":[[2022,10,24]]},"abstract":"<jats:p>&lt;b&gt;&lt;br&gt;Introduction:&lt;\/b&gt; Dupuytren\u2019s disease is a common fibrotic disorder of the palmar aponeurosis characterized by the formation of  nodules and cords, as well as development of progressive flexion deformities in the digits, leading to functional impairment.  Surgical excision of the affected aponeurosis remains the most common treatment. Quite a few new information appeared  about epidemiology, pathogenesis and particularly treatment of the disorder.&lt;\/br&gt;  &lt;b&gt;&lt;br&gt;Aim:&lt;\/b&gt; The aim of this study is an updated review of scientific data in this topic.&lt;\/br&gt;  &lt;b&gt;&lt;br&gt;Results:&lt;\/b&gt; Results of epidemiologic studies showed that Dupuytren\u2019s disease is not so uncommon in Asian and African population as it was earlier believed. An important role of genetic factors on development of the disease in a proportion of patients  was demonstrated, however, it did not translate neither to the treatment nor to the prognosis. The most changes concerned  the management of Dupuytren\u2019s disease. A positive effect of steroids injections into the nodules and cords for inhibition of  the disease in early stages was shown. In the advanced stages, a standard technique of partial fasciectomy was partly replaced  by mini-invasive methods such as needle fasciotomy and collagenase Clostirdium hystolyticum injections. Unexpected withdrawal of collagenase from the market in 2020 resulted in considerable limitation of the availability of this treatment.&lt;\/br&gt;  &lt;b&gt;&lt;br&gt;Conclusion:&lt;\/b&gt; It seems that updated knowledge on Dupuytren\u2019s disease may be interested and useful for surgeons involved in  management of the disorder.&lt;\/br&gt;<\/jats:p>","DOI":"10.5604\/01.3001.0016.0058","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T07:51:18Z","timestamp":1674719478000},"page":"53-61","source":"Crossref","is-referenced-by-count":5,"title":["Dupuytren\u2019s disease \u2013 what\u2019s new: a review"],"prefix":"10.5604","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0618-2488","authenticated-orcid":false,"given":"Andrzej","family":"\u017byluk","sequence":"first","affiliation":[{"name":"Department of General and Hand Surgery, Pomeranian Medical University in Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3689","reference":[{"key":"231280r1","unstructured":"Bayat A.: Cell biology and Dupuytren\u2019s disease. W: Dupuytren\u2019s disease. FESSHInstructional Course, red. D. Warwick. CG Edizioni Medico Scientifiche, Torino 2015, 30\u201336."},{"key":"231280r2","doi-asserted-by":"crossref","unstructured":"Hart M.G., Hooper G.: Clinical associations of Dupuytren\u2019s disease. PostgradMed J., 2005; 81: 425\u2013428.","DOI":"10.1136\/pgmj.2004.027425"},{"key":"231280r3","doi-asserted-by":"crossref","unstructured":"Ruettermann M., Hermann R.M., Khatib-Chahidi K., Werker P.: Dupuytren\u2019s disease - aetiology and treatment. Dtsch Arztebl Int, 2021; 118: 781\u2013788.","DOI":"10.3238\/arztebl.m2021.0325"},{"key":"231280r4","unstructured":"\u017byluk A.: Genetyczna sk\u0142onno\u015b\u0107 do choroby Dupuytrena: przegl\u0105d pi\u015bmiennictwa. Pol Przegl Chir, 2008; 80: 162\u2013169."},{"key":"231280r5","unstructured":"Dias J.: Dupuytren\u2019s contracture: recurrence, unanswered questions and costs.W: Dupuytren\u2019s disease. FESSH Instructional Course, red. D. Warwick. CGEdizioni Medico Scientifiche, Torino 2015, 227\u2013236."},{"key":"231280r6","doi-asserted-by":"crossref","unstructured":"Tajika T., Kobayashi T., Kaneko T., Tsunoda D., Tsunoda K. et al.: Epidemiological study for personal risk factors and quality of life related to Dupuytren\u2019sdisease in a mountian village of Japan. J Orthop Sci, 2014; 19: 64\u201370.","DOI":"10.1007\/s00776-013-0478-y"},{"key":"231280r7","doi-asserted-by":"crossref","unstructured":"Lanting R., van den Heuvel E.R., Werker P.M.: Clusters in short-term disease coursein participants with primary Dupuytren disease. J Hand Surg Am., 2016; 41: 354\u2013361.","DOI":"10.1016\/j.jhsa.2015.10.027"},{"key":"231280r8","doi-asserted-by":"crossref","unstructured":"Warwick D., Werker P.N., Pess G., Hirata H., Hunter-Smith D.J.: Dupuytren\u2019sdisease: using needles more across the world. J Hand Surg Eur., 2022; 47: 80\u201388.","DOI":"10.1177\/17531934211043307"},{"key":"231280r9","doi-asserted-by":"crossref","unstructured":"\u017byluk A., D\u0119bniak T.: Common variants of the ALDH2 and DHDH genes andthe risk of Dupuytren`s disease. J Hand Surg Eur., 2013; 38: 430\u2013434.","DOI":"10.1177\/1753193412471502"},{"key":"231280r10","doi-asserted-by":"crossref","unstructured":"Ng M., Thakkar D., Southam L. et al.: A genome-wide association study ofDupuytren disease reveals 17 additional variants implicated in fibrosis. Am JHum Genet, 2017; 101: 417\u2013427.","DOI":"10.1016\/j.ajhg.2017.08.006"},{"key":"231280r11","doi-asserted-by":"crossref","unstructured":"Broekstra D.C., Groen H., Molenkamp S., Werker P.M.N., van den Heuvel E.R.:A systematic review and meta-analysis on the strength and consistency of theassociations between Dupuytren disease and diabetes mellitus, liver diseaseand epilepsy. Plast Reconstr Surg., 2018; 141: 367e\u2013379e.","DOI":"10.1097\/PRS.0000000000004120"},{"key":"231280r12","unstructured":"\u017byluk A., Puchalski P.: Hand disorders associated with diabetes: a review. ActaOrthop Belg, 2015; 81: 191\u2013196."},{"key":"231280r13","unstructured":"\u017byluk A., D\u0119bniak T.: Wsp\u00f3\u0142istnienie choroby Dupuytrena i nowotwor\u00f3wz\u0142o\u015bliwych: przegl\u0105d pi\u015bmiennictwa. Ann Acad Med Stetin, 2013; 59: 25\u201327."},{"key":"231280r14","doi-asserted-by":"crossref","unstructured":"\u017byluk A., Paszkowska-Szczur K., Gupta S. et al.: Dupuytren\u2019s disease andrisk of malignat neoplasms. Hered Cancer Med Pract., 2014; 12(1): 6. doi:10.1186\/1867-4287-12-6.","DOI":"10.1186\/1897-4287-12-6"},{"key":"231280r15","doi-asserted-by":"crossref","unstructured":"Ball C, Izadi D., Verjee L.S., Chan J., Nanchahal J.: Systematic review of non--surgical treatments for early Dupuytren\u2019s disease. BMC Muscul Dis., 2016;17: 345. doi: 10.1186\/s12891-016-1200-y.","DOI":"10.1186\/s12891-016-1200-y"},{"key":"231280r16","doi-asserted-by":"crossref","unstructured":"Ketchum L.D., Donahue T.K.: The injection of nodules of Dupuytren\u2019s diseasewith triamcinolone acetonide. J Hand Surg Am., 2000; 25: 1157\u20131162.","DOI":"10.1053\/jhsu.2000.18493"},{"key":"231280r17","doi-asserted-by":"crossref","unstructured":"Nanchahal J., Ball C., Davidson D. et al.: Anti-tumour necrosis factor therapyfor Dupuytren\u2019s disease: a randomised dose response proof of concept phase2a clinical trial. EBio Medicine, 2018; 33: 282\u2013288.","DOI":"10.1016\/j.ebiom.2018.06.022"},{"key":"231280r18","doi-asserted-by":"crossref","unstructured":"Larocerie-Salgado J., Davidson J.: Nonoperative treatment of PIPJ flexion contractures associated with Dupuytren\u2019s disease. J Hand Surg Eur., 2012; 37: 722\u2013727.","DOI":"10.1177\/1753193411422680"},{"key":"231280r19","doi-asserted-by":"crossref","unstructured":"Christie W.S., Puhl A.A., Lucaciu O.C.: Cross-frictional therapy and stretchingfor the treatment of palmar adhesions due to Dupuytren\u2019s contracture: a prospective case study. Man Ther, 2012; 17: 479\u2013482.","DOI":"10.1016\/j.math.2011.11.001"},{"key":"231280r20","doi-asserted-by":"crossref","unstructured":"Adamietz B., Keilholz L., Grunert J., Sauer R.: Radiotherapy of early stage Dupuytren disease. Long-term results after a median follow-up period of 10 years.Strahlenther Onkol., 2001; 177: 604\u2013610.","DOI":"10.1007\/PL00002371"},{"key":"231280r21","unstructured":"Weinzierl G., Flugel M., Geldmacher J.: Lack of effectiveness of alternative non-surgical treatment procedures of Dupuytren contracture. Chirurg, 1993; 64: 492\u2013494."},{"key":"231280r22","doi-asserted-by":"crossref","unstructured":"Foucher G., Medina J., Navarro P.: Percutaneous needle aponeurectomy: complications and results. J Hand Surg Br., 2003; 28: 427\u2013431.","DOI":"10.1016\/S0266-7681(03)00013-5"},{"key":"231280r23","doi-asserted-by":"crossref","unstructured":"Pess G.M., Pess R.M., Pess R.A.: Results of needle aponeurectomy for Dupuytren\u2019s contracture in over 1000 fingers. J Hand Surg Am., 2012; 37: 651\u2013656.","DOI":"10.1016\/j.jhsa.2012.01.029"},{"key":"231280r24","doi-asserted-by":"crossref","unstructured":"Tuncel U., Kurt A., Gumus M. et al.: Preliminary results with non-centrifugedautologous fat graft and percutaneous aponeurotomy for treating Dupuytren\u2019sdisease. Hand Surg Rehabil., 2017; 36: 350\u2013354.","DOI":"10.1016\/j.hansur.2017.05.004"},{"key":"231280r25","doi-asserted-by":"crossref","unstructured":"Hovius S.E., Kan H.J., Verhoekx J.S., Khouri R.K.: Percutaneous aponeurotomyand lipofilling (PALF): a regenerative approach to dupuytren contracture. ClinPlast Surg., 2015; 42: 375\u2013381.","DOI":"10.1016\/j.cps.2015.03.006"},{"key":"231280r26","doi-asserted-by":"crossref","unstructured":"Selles R.W., Zhou C., Kan H.J. et al.: Percutaneous aponeurotomy and lipofilling versus limited fasciectomy for dupuytren\u2019s contracture: 5-year resultsfrom a randomized clinical trial. Plast Reconstr Surg., 2018; 142: 1523\u20131531.","DOI":"10.1097\/PRS.0000000000004982"},{"key":"231280r27","doi-asserted-by":"crossref","unstructured":"Sambuy M.T.C., Nakamoto H.A., Bolliger R. et al.: Randomized controlled trialof limited fasciotomy with injection of adipose graft for dupuytren\u2019s disease.Acta Ortop Bras., 2020; 28: 159\u2013164.","DOI":"10.1590\/1413-785220202804233522"},{"key":"231280r28","doi-asserted-by":"crossref","unstructured":"Coleman S., Gilpin D., Kaplan F.T. et al.: Efficacy and safety of concurrent collagenase clostridium hystolyticum injections for multiple Dupuytren\u2019s contractures. J Hand Surg Am., 2014; 39: 57\u201364.","DOI":"10.1016\/j.jhsa.2013.10.002"},{"key":"231280r29","doi-asserted-by":"crossref","unstructured":"Verheyden J.R.: Early outcomes of a sequential series of 144 patients with Dupuytren\u2019s contracture treated by collagenase injection using an increased dose,multi-cord technique. J Hand Surg Eur,, 2015; 40: 133\u2013140.","DOI":"10.1177\/1753193414530590"},{"key":"231280r30","doi-asserted-by":"crossref","unstructured":"Werlinrud J.C., Hansen K.L., Larsen L., Lauritsen J.: Results after collagenasetreatment of Dupuytren\u2019s disease. J Hand Surg Eur, 2018; 43: 814\u2013817.","DOI":"10.1177\/1753193418790157"},{"key":"231280r31","doi-asserted-by":"crossref","unstructured":"Brazzelli M., Cruickshank M., Tassie E. et al.: Collagenase clostridium histolyticum for the treatment of Dupuytren\u2019s contracture: systematic review andeconomic evaluation. Health Technol Assess., 2015; 19: 1\u2013202. doi: 10.3310\/hta19900.","DOI":"10.3310\/hta19900"},{"key":"231280r32","doi-asserted-by":"crossref","unstructured":"Stromberg J., Ibsen Sorensen A., Friden J.: Percutaneous needle fasciotomy vscollagenase treatmernt for Dupuytren\u2019s contracture: a randomized controlledtrial with a two-year follow-up. J Bone Joint Surg Am., 2018; 100: 1079\u20131086.","DOI":"10.2106\/JBJS.17.01128"},{"key":"231280r33","doi-asserted-by":"crossref","unstructured":"Sanjuan-Cerver\u00f3 R., Carrera-Hueso F.J., Vazquez-Ferreiro P.: Adverse effectsassociated with collagenase clostridium histolyticum in Dupuytren disease:A prospective study. Orthop Traumatol Surg Res., 2018; 104: 901\u2013905.","DOI":"10.1016\/j.otsr.2018.05.012"},{"key":"231280r34","doi-asserted-by":"crossref","unstructured":"Arora R., Angermann P., Aspalter P. et al.: Prospective observation of Clostridium histolyticum collagenase for the treatment of Dupuytren\u2019s disease in 788 patients: the Austrian register. Arch Orthop Trauma Surg., 2019; 139: 1315\u20131321.","DOI":"10.1007\/s00402-019-03226-3"},{"key":"231280r35","doi-asserted-by":"crossref","unstructured":"Sanjuan-Cerver\u00f3 R., Carrera-Hueso F.J., Vazquez-Ferreiro P., Ramon-BarriosM.A.: Efficacy and adverse effects of collagenase use in the treatment of Dupuytren\u2019s disease: a metaanalysis. Bone Joint J., 2018; 100-B: 73\u201380.","DOI":"10.1302\/0301-620X.100B1.BJJ-2017-0463.R1"},{"key":"231280r36","doi-asserted-by":"crossref","unstructured":"Krefter C., Marks M., Hensler S., Herren D., Calcagni M.: Complications aftertreating Dupuytren\u2019s disease. A systematic literature review. Hand Surg Rehabil, 2017; 36: 322\u2013329.","DOI":"10.1016\/j.hansur.2017.07.002"},{"key":"231280r37","doi-asserted-by":"crossref","unstructured":"Povlsen B., Singh S.: Acute double flexor tendon ruptures following injectionof collagenase clostridium histolyticum (Xiapex) for Dupuytren\u2019s contracture.BMJ Case Rep., 2014; doi: 10.1136\/bcr-2013-203338 1.","DOI":"10.1136\/bcr-2013-203338"},{"key":"231280r38","doi-asserted-by":"crossref","unstructured":"Wozniczka J., Canepa C., Mirarchi A., Solomon J.S.: Complications following collagenase treatment for Dupuytren\u2019s contracture. Hand, 2017; 12: NP148\u2013NP151.","DOI":"10.1177\/1558944717711461"},{"key":"231280r39","doi-asserted-by":"crossref","unstructured":"Kawano Y., Hagiwara T., Tanaka N. et. al.: Vascular complication after collagenase injection and manipulation for Dupuytren\u2019s contracture: a case report.JMAJ, 2019; 2: 196\u2013199.","DOI":"10.31662\/jmaj.2018-0063"},{"key":"231280r40","doi-asserted-by":"crossref","unstructured":"Rozen W.M., Edirisinghe Y., Crock J.: Late complications of clinical clostridiumhistolyticum collagenase use in Dupuytren\u2019s disease. PloS One, 2012; 7: e43406.","DOI":"10.1371\/journal.pone.0043406"},{"key":"231280r41","doi-asserted-by":"crossref","unstructured":"Richards K., Sethu C., Tiernan E.: Phalangeal fracture leading to digital amputation, sustained during manipulation for Dupuytren\u2019s disease as part of clostridial collagenase treatment. Ann R Coll Surg Engl., 2019; 101: e102\u2013e104.","DOI":"10.1308\/rcsann.2019.0019"},{"key":"231280r42","doi-asserted-by":"crossref","unstructured":"\u017byluk A.: Recurrence of Dupuytren\u2019s disease following surgery \u2013 an analysis ofthe causes and incidence. Pomeranian J Life Sci, 2020; 66: 34\u201336.","DOI":"10.21164\/pomjlifesci.743"}],"container-title":["Polish Journal of Surgery"],"original-title":[],"link":[{"URL":"https:\/\/ppch.pl\/gicid\/pdf\/01.3001.0016.0058","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ppch.pl\/gicid\/pdf\/01.3001.0016.0058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T07:48:13Z","timestamp":1701935293000},"score":1,"resource":{"primary":{"URL":"https:\/\/ppch.pl\/gicid\/01.3001.0016.0058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,24]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,8,12]]}},"URL":"https:\/\/doi.org\/10.5604\/01.3001.0016.0058","relation":{},"ISSN":["0032-373X","2299-2847"],"issn-type":[{"value":"0032-373X","type":"print"},{"value":"2299-2847","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,24]]}}}